Search

Guidelines Committee

Current committee members
Carlo Dufour, Italy (Chair)
Martin Dreyling, Germany (Vice-Chair)
Steffen Koschmieder, Germany (Executive member)
Marieke Kruip, The Netherlands (Executive member)
Area associate members
Tamam Bakchoul, Germany
Sabine Blum, Switzerland
Cristina Castilla Llorente, France
Lydie Da Costa, France
Wojciech Jurczak, Poland
Noémi Roy, United Kingdom
Giovanna Russo, Italy
Cynthia So-Osman, The Netherlands
AimThe…

Adolescents and young adults (AYA)

Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.

Presentations

EHA-SfPM Precision Medicine Meeting - Presentations

…

Scientific Program Committee, EHA2025 Congress

Current committee members
Martin Dreyling, Germany (Chair)
Brian Huntly, United Kingdom (Past Chair)
Meritxell Alberich Jordà, Czechia (Chair elect)
Paolo Corradini, Italy (Local representative)
Gabriela Baerlocher, Switzerland
Valentine Brousse, France
Mattia D'Agostino, Italy
Mariane de Montalembert, France
Jordi Esteve, Spain
Thierry Facon, France
Thoas Fioretos, Sweden
Krzystof Giannopoulos, Poland
Shahram Kordasti, United Kingdom
Georg…

SPC Advisory Board, EHA2025 Congress

Current committee members
Lorena Arranz, Norway
Peter Borchmann, Germany
Veronika Buxhofer-Ausch, Austria
Ana Cvejic, Denmark
Matteo Della Porta, Italy
Michael Doubek, Czechia
Andreas Glenthøj, Denmark
Maria Gomes da Silva, Portugal
Julia Hauer, Germany
Daniel Hodson, United Kingdom
Cristina João, Portugal
Sören Lehmann, Sweden
Tamás Masszi, Hungary
Karinna Meijer, The Netherlands
Jamie O'Sullivan, Ireland
Cristina Papayannidis, Italy
France…

Meeting Program

Please click on the image to open the program-at-a-glance. *The full program will become available in the coming weeks.

Substances of Human Origin (SoHO) legislation

EHA’s involvementEHA has been involved in both the evaluation and subsequent revision of the EU legislation on human blood and blood components. The evaluation of these rules, which dated back to 2002, began in 2016.